Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 15, 2007

Champions Biotechnology Obtains BPU Patents

  • Champions Biotechnology obtained  patent rights encompassing two benzoylphenylurea (BPU) sulfur analog compounds that they report has shown potent activity against prostate and pancreatic cancer cell lines.

    BPU is an antimitotic inhibitor that targets microtubule-associated protein tau deficient tumors, a common feature of solid tumors. These inhibitors have performed better than Docetaxel (Taxotere) in direct-patient xenograft models of pancreatic cancer, according to the company.

    The company, in exchange for 550,000 restricted shares of its common stock, was assigned all the rights in the U.S. and in foreign countries to the applications for these inhibitors developed at Johns Hopkins University.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »